Consent, commodification and benefit-sharing in genetic research.

Area of Science:

• Biotechnology Law and Ethics
• Bioethics
• Intellectual Property Law

Background:

• The biotechnology industry is a rapidly growing global market, estimated at $17 billion in 2000.
• The legal framework governing biotechnology, particularly concerning human tissue and genetic material, is underdeveloped.
• Existing laws and landmark cases (e.g., Moore, Chakrabarty) offer limited control over economic interests in biotechnology.

Purpose of the Study:

• To examine the ethical and legal challenges in the biotechnology industry, focusing on the commodification of human biological materials.
• To analyze the adequacy of current legal and consent-based approaches in protecting vulnerable populations.
• To explore the concept of injustice in the context of human tissue and genome commercialization.

Main Methods:

• Review of existing medical and patent law.
• Analysis of legal cases such as Moore and Chakrabarty.
• Examination of developments in consent procedures and intellectual property consultations.
• Consideration of perspectives from vulnerable genetic communities.

Main Results:

• The biotechnology sector faces significant ethical and legal gaps, akin to a 'gold rush' with potential for exploitation.
• Current legal frameworks struggle to regulate powerful economic interests in human genetic resources.
• Developments in consent procedures acknowledge power imbalances but do not fully resolve the ethical concerns of commodification.

Conclusions:

• Refined consent procedures are a step towards protecting vulnerable genetic communities in biotechnology research.
• The fundamental ethical questions surrounding the commodification of human tissue and the genome remain unresolved.
• Further legal and ethical deliberation is needed to address the inherent injustices in the biotechnology "gold rush."